Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the 4–10 sequence of adrenocorticotropic hormone (ACTH), with a Pro-Gly-Pro extension at the C-terminus that confers enzymatic stability against peptidase cleavage. It was developed in Russia in the late 1980s and early 1990s and has been studied in the neuropharmacology research literature.

Research in rodent models has reported dose-dependent increases in BDNF (brain-derived neurotrophic factor) mRNA in hippocampal tissue, with corresponding modulation of the BDNF/TrkB signaling axis. Effects on dopaminergic and serotonergic neurotransmission have been reported in rodent brain microdialysis studies. The peptide has been reported to cross the blood-brain barrier following intranasal administration in rodent models. Receptor-level specificity has not been definitively established in the published literature.

Used in rodent models of cognitive function, hippocampal neurogenesis assays, BDNF expression studies, and stroke / cerebral ischemia models.

Every batch ships with a third-party Certificate of Analysis documenting identity, lot-specific HPLC purity, mass spectrometry confirmation, and storage conditions. The COA is downloadable from the buyer's account dashboard and QR-linked on the vial label. Purity claims are per lot, not per product — see the FAQ for the framing.

Sold under one of two B2B buyer categories: research institutions for in vitro work under the RUO designation, or licensed 503A compounding pharmacies as an API for patient-specific compounded preparations under USP <797> or <795>. Accounts are manually reviewed; pending accounts cannot place orders or view pricing.

The full regulatory framing, including what we are not (we are not a 503B outsourcing facility and do not compound finished drugs), is in the disclaimer.